Drug reference
ibrexafungerp
Triterpenoid (glucan synthase inhibitor)
Triterpenoid (glucan synthase inhibitor)
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
X
FDA category + note
Mechanism
An oral antifungal agent belonging to a new class of glucan synthase inhibitors called triterpenoids, with potent activity against Candida species. Maintains antifungal efficacy at low pH.
Indications
Treatment of vulvovaginal candidiasisTreatment of recurrent vulvovaginal candidiasis
Pregnancy & lactation
Pregnancy
X
Lactation
Contraindicated in lactating women.
Related guidelines
Ask House about ibrexafungerp
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Harrison 22e·Verified: 2026-05-10 · House clinical team